Showing 761 - 780 results of 100,884 for search '(( 5 we decrease ) OR ( 5 ((step decrease) OR (((teer decrease) OR (a decrease)))) ))', query time: 1.57s Refine Results
  1. 761
  2. 762
  3. 763

    Procedure related data, LBNP, LBPP and hypoxia. by Marcus Thudium (6441863)

    Published 2023
    “…Decreasing levels of LBNP were applied in 5-minute steps until subjects reached presyncope. …”
  4. 764

    Individual biometric data of patients. by Marcus Thudium (6441863)

    Published 2023
    “…Decreasing levels of LBNP were applied in 5-minute steps until subjects reached presyncope. …”
  5. 765
  6. 766
  7. 767
  8. 768
  9. 769
  10. 770
  11. 771
  12. 772
  13. 773
  14. 774
  15. 775
  16. 776
  17. 777
  18. 778

    Image_5_GM-CSF-activated STAT5A regulates macrophage functions and inflammation in atherosclerosis.png by Jan Nagenborg (14771194)

    Published 2023
    “…</p>Methods and results<p>Here, we demonstrate reciprocal expression regulation of STAT5A and STAT5B in human atherosclerotic lesions. …”
  19. 779

    Discovery of the Triazolo[1,5‑<i>a</i>]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance... by Shuai Wang (109515)

    Published 2021
    “…Here, we reported our medicinal chemistry efforts that led to the discovery of the triazolo­[1,5-<i>a</i>]­pyrimidine derivative <b>WS-898</b> as a highly effective ABCB1 inhibitor capable of reversing paclitaxel (PTX) resistance in drug-resistant SW620/Ad300, KB-C2, and HEK293/ABCB1 cells (IC<sub>50</sub> = 5.0, 3.67, and 3.68 nM, respectively), more potent than verapamil and zosuquidar. …”
  20. 780

    Discovery of the Triazolo[1,5‑<i>a</i>]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance... by Shuai Wang (109515)

    Published 2021
    “…Here, we reported our medicinal chemistry efforts that led to the discovery of the triazolo­[1,5-<i>a</i>]­pyrimidine derivative <b>WS-898</b> as a highly effective ABCB1 inhibitor capable of reversing paclitaxel (PTX) resistance in drug-resistant SW620/Ad300, KB-C2, and HEK293/ABCB1 cells (IC<sub>50</sub> = 5.0, 3.67, and 3.68 nM, respectively), more potent than verapamil and zosuquidar. …”